Land: Den Europæiske Union
Sprog: engelsk
Kilde: EMA (European Medicines Agency)
fluoxetine
Forte Healthcare Limited
QN06AB03
fluoxetine
Dogs
Psychoanaleptics
As an aid in the treatment of separation-related disorders in dogs manifested by destruction and inappropriate behaviours (vocalisation and inappropriate defecation and / or urination) and only in combination with behavioural-modification techniques.
Revision: 14
Authorised
2008-07-08
14 B. PACKAGE LEAFLET 15 PACKAGE LEAFLET: RECONCILE 8 MG CHEWABLE TABLETS FOR DOGS RECONCILE 16 MG CHEWABLE TABLETS FOR DOGS RECONCILE 32 MG CHEWABLE TABLETS FOR DOGS RECONCILE 64 MG CHEWABLE TABLETS FOR DOGS 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder: FORTE Healthcare ltd Cougar Lane Naul Co. Dublin Ireland Manufacturer responsible for batch release: Tairgi Tread -Lia Baile na Sceilge Teo T/A Ballinskelligs Veterinary Products, Ballinskelligs, Co. Kerry, V23 XR52, Ireland 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Reconcile 8 mg chewable tablets for dogs Reconcile 16 mg chewable tablets for dogs Reconcile 32 mg chewable tablets for dogs Reconcile 64 mg chewable tablets for dogs fluoxetine 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each tablet contains: Reconcile 8 mg: fluoxetine 8 mg (equivalent to 9.04 mg fluoxetine hydrochloride) Reconcile 16mg: fluoxetine 16 mg (equivalent to 18.08mg fluoxetine hydrochloride) Reconcile 32 mg: fluoxetine 32 mg (equivalent to 36.16 mg fluoxetine hydrochloride) Reconcile 64 mg: fluoxetine 64 mg (equivalent to 72.34 mg fluoxetine hydrochloride) Speckled, tan to brown round chewable tablets, embossed on one side with a number (as listed below): Reconcile 8 mg tablets: 4203 Reconcile 16 mg tablets: 4205 Reconcile 32 mg tablets: 4207 Reconcile 64 mg tablets: 4209 4. INDICATION(S) 16 As an aid in the treatment of separation-related disorders in dogs, such as destruction and vocalisation and inappropriate defaecation and/or urination. This product should only be used in conjunction with a behaviour modification programme recommended by your veterinary surgeon. 5. CONTRAINDICATIONS Do not use in dogs weighing less than 4 kg. Do not use in dogs with epilepsy or a history of seizures. Do not use in case of hypersensitivity to fluoxetine or other Selective Serotonin Re-Uptake Inhibitors (SSRIs) or to any of the excipients. 6. ADVERSE Læs hele dokumentet
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Reconcile 8 mg chewable tablets for dogs Reconcile 16mg chewable tablets for dogs Reconcile 32 mg chewable tablets for dogs Reconcile 64 mg chewable tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: Each tablet contains: Reconcile 8 mg: Fluoxetine 8 mg (equivalent to 9.04 mg fluoxetine hydrochloride) Reconcile 16mg: Fluoxetine 16 mg (equivalent to 18.08mg fluoxetine hydrochloride) Reconcile 32 mg: Fluoxetine 32 mg (equivalent to 36.16 mg fluoxetine hydrochloride) Reconcile 64 mg: Fluoxetine 64 mg (equivalent to 72.34 mg fluoxetine hydrochloride) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Chewable tablet. Speckled, tan to brown round chewable tablets, embossed on one side with a number (as listed below): Reconcile 8 mg tablets: 4203 Reconcile 16 mg tablets: 4205 Reconcile 32 mg tablets: 4207 Reconcile 64 mg tablets: 4209 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES As an aid in the treatment of separation-related disorders in dogs manifested by destruction and inappropriate behaviours (vocalisation and inappropriate defaecation and/or urination) and only in combination with behavioural modification techniques. 4.3 CONTRAINDICATIONS Do not use in dogs weighing less than 4 kg. Do not use in dogs with epilepsy or in dogs with a history of seizures. Do not use in case of hypersensitivity to fluoxetine or other Selective Serotonin Re-Uptake Inhibitors (SSRIs) or to any of the excipients. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 3 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals The safety of the product has not been established in dogs less than 6 months of age or weighing less than 4 kg. Though rare, seizures may occur in dogs treated with Reconcile. Treatment should be stopped if seizures occur. Special precautions to be taken by the person administering the veterinary medicinal pr Læs hele dokumentet